The preclinical study of 177Lu-DOTA-LTVSPWY as a potential therapeutic agent against HER2 overexpressed cancer
Background Peptide receptor radionuclide therapy (PRRT) has evolved in cancer therapy and diagnosis. LTVSPWY, as a peptide, can target HER2 receptor; on the other hand, 177Lu emits $ β^{−} $ which is helpful for cancer therapy. The radiolabeling of LTVSPWY with 177Lu results in a therapeutic agent (177Lu-DOTA-LTVSPWY) capable of cancer treatment. Methods 177Lu-DOTA-LTVSPWY was prepared with high radiochemical purity (RCP). The stability was investigated in saline and human serum. The radiotracer affinity toward the SKOV-3 cell line with overexpression of the HER2 receptor was evaluated. Then the impact of the radiotracer on the colony formation of the SKOV-3 cell line was investigated with colony assay. Moreover, the biodistribution of this radiotracer in SKOV-3 xenograft tumor-bearing nude mice were also studied to determine the radiotracer accumulation in the tumor site. The mice were treated with 177Lu-DOTA-LTVSPWY and subjected to histopathological evaluation. Results The RCP of 177Lu-DOTA-LTVSPWY after radiolabeling and stability tests was more than 97.7%. The radiotracer displayed high affinity toward the SKOV-3 cell line (KD = 6.6 ± 3.2 nM). Treatment of the SKOV-3 cell line with the radiotracer reduces the SKOV-3 colony survival to less than 3% for 5 MBq of the radiotracer. Tumor-to-muscle (T/M) ratio is the highest at 48 h and 1 h post-injection (2.3 and 4.75, respectively). The histopathological study also confirms the cellular damage to the tumor tissue. Conclusions 177Lu-DOTA-LTVSPWY can recognize HER2 receptors in vivo and in vitro; hence, it can serve as a therapeutic agent..
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2023 |
---|---|
Erschienen: |
2023 |
Enthalten in: |
Zur Gesamtaufnahme - volume:37 |
---|---|
Enthalten in: |
Annals of nuclear medicine - 37(2023), 7 vom: 28. Apr., Seite 400-409 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Molavipordanjani, Sajjad [VerfasserIn] |
---|
Links: |
Volltext [lizenzpflichtig] |
---|
Themen: |
---|
Anmerkungen: |
© The Author(s) under exclusive licence to The Japanese Society of Nuclear Medicine 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. |
---|
doi: |
10.1007/s12149-023-01839-8 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
SPR051981319 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | SPR051981319 | ||
003 | DE-627 | ||
005 | 20230622064745.0 | ||
007 | cr uuu---uuuuu | ||
008 | 230622s2023 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1007/s12149-023-01839-8 |2 doi | |
035 | |a (DE-627)SPR051981319 | ||
035 | |a (SPR)s12149-023-01839-8-e | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Molavipordanjani, Sajjad |e verfasserin |4 aut | |
245 | 1 | 4 | |a The preclinical study of 177Lu-DOTA-LTVSPWY as a potential therapeutic agent against HER2 overexpressed cancer |
264 | 1 | |c 2023 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
500 | |a © The Author(s) under exclusive licence to The Japanese Society of Nuclear Medicine 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. | ||
520 | |a Background Peptide receptor radionuclide therapy (PRRT) has evolved in cancer therapy and diagnosis. LTVSPWY, as a peptide, can target HER2 receptor; on the other hand, 177Lu emits $ β^{−} $ which is helpful for cancer therapy. The radiolabeling of LTVSPWY with 177Lu results in a therapeutic agent (177Lu-DOTA-LTVSPWY) capable of cancer treatment. Methods 177Lu-DOTA-LTVSPWY was prepared with high radiochemical purity (RCP). The stability was investigated in saline and human serum. The radiotracer affinity toward the SKOV-3 cell line with overexpression of the HER2 receptor was evaluated. Then the impact of the radiotracer on the colony formation of the SKOV-3 cell line was investigated with colony assay. Moreover, the biodistribution of this radiotracer in SKOV-3 xenograft tumor-bearing nude mice were also studied to determine the radiotracer accumulation in the tumor site. The mice were treated with 177Lu-DOTA-LTVSPWY and subjected to histopathological evaluation. Results The RCP of 177Lu-DOTA-LTVSPWY after radiolabeling and stability tests was more than 97.7%. The radiotracer displayed high affinity toward the SKOV-3 cell line (KD = 6.6 ± 3.2 nM). Treatment of the SKOV-3 cell line with the radiotracer reduces the SKOV-3 colony survival to less than 3% for 5 MBq of the radiotracer. Tumor-to-muscle (T/M) ratio is the highest at 48 h and 1 h post-injection (2.3 and 4.75, respectively). The histopathological study also confirms the cellular damage to the tumor tissue. Conclusions 177Lu-DOTA-LTVSPWY can recognize HER2 receptors in vivo and in vitro; hence, it can serve as a therapeutic agent. | ||
650 | 4 | |a Therapy |7 (dpeaa)DE-He213 | |
650 | 4 | |a Lu |7 (dpeaa)DE-He213 | |
650 | 4 | |a LTVSPWY |7 (dpeaa)DE-He213 | |
650 | 4 | |a PRRT |7 (dpeaa)DE-He213 | |
650 | 4 | |a Radiolabeled peptide |7 (dpeaa)DE-He213 | |
650 | 4 | |a HER2 |7 (dpeaa)DE-He213 | |
700 | 1 | |a Mousavi, Tahoora |4 aut | |
700 | 1 | |a Khorramimoghaddam, Alireza |4 aut | |
700 | 1 | |a Talebpour Amiri, Fereshteh |4 aut | |
700 | 1 | |a Abedi, Seyed Mohammad |4 aut | |
700 | 1 | |a Hosseinimehr, Seyed Jalal |0 (orcid)0000-0001-8055-8036 |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Annals of nuclear medicine |d [S.l.] : Springer Japan, 1987 |g 37(2023), 7 vom: 28. Apr., Seite 400-409 |w (DE-627)SPR024494089 |w (DE-600)2039738-0 |x 1864-6433 |7 nnns |
773 | 1 | 8 | |g volume:37 |g year:2023 |g number:7 |g day:28 |g month:04 |g pages:400-409 |
856 | 4 | 0 | |u https://dx.doi.org/10.1007/s12149-023-01839-8 |z lizenzpflichtig |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_SPRINGER | ||
951 | |a AR | ||
952 | |d 37 |j 2023 |e 7 |b 28 |c 04 |h 400-409 |